CenterBook Partners LP Takes Position in Liquidia Technologies, Inc. (NASDAQ:LQDA)

Key Points

• CenterBook Partners LP has invested approximately $1.79 million in Liquidia Technologies, acquiring 121,072 shares, which represents about 0.14% of the company.
• Liquidia Technologies reported earnings per share (EPS) of ($0.45), missing estimates, and had a revenue of $3.12 million in its latest quarterly earnings.
• Institutional investors currently own 64.54% of Liquidia Technologies' stock, indicating strong interest from financial institutions.

CenterBook Partners LP bought a new position in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 121,072 shares of the company's stock, valued at approximately $1,786,000. CenterBook Partners LP owned about 0.14% of Liquidia Technologies at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Corebridge Financial Inc. grew its position in Liquidia Technologies by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock worth $371,000 after purchasing an additional 694 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Liquidia Technologies by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares during the period. Cetera Investment Advisers lifted its stake in shares of Liquidia Technologies by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after acquiring an additional 1,277 shares during the period. Valmark Advisers Inc. lifted its stake in shares of Liquidia Technologies by 7.4% in the 1st quarter. Valmark Advisers Inc. now owns 18,641 shares of the company's stock worth $275,000 after acquiring an additional 1,283 shares during the period. Finally, Bleakley Financial Group LLC lifted its stake in shares of Liquidia Technologies by 6.4% in the 1st quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company's stock worth $373,000 after acquiring an additional 1,523 shares during the period. Institutional investors own 64.54% of the company's stock.

Insider Buying and Selling at Liquidia Technologies

In other news, CFO Michael Kaseta sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $20.00, for a total transaction of $600,000.00. Following the sale, the chief financial officer owned 376,412 shares in the company, valued at $7,528,240. The trade was a 7.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason Adair sold 2,576 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $14.28, for a total transaction of $36,785.28. Following the sale, the insider owned 193,634 shares in the company, valued at $2,765,093.52. This represents a 1.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,277 shares of company stock valued at $1,469,392 over the last three months. 26.50% of the stock is owned by insiders.

Liquidia Technologies Price Performance

LQDA stock traded up $1.24 on Friday, hitting $20.45. 2,372,133 shares of the company's stock traded hands, compared to its average volume of 2,532,096. Liquidia Technologies, Inc. has a 1-year low of $8.26 and a 1-year high of $20.64. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -12.94 and a beta of 0.14. The stock has a fifty day moving average of $15.59 and a 200-day moving average of $15.16. The company has a current ratio of 2.93, a quick ratio of 2.91 and a debt-to-equity ratio of 2.08.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. The business had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. On average, analysts forecast that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on LQDA shares. Wells Fargo & Company upped their price target on shares of Liquidia Technologies from $23.00 to $25.00 and gave the stock an "overweight" rating in a research note on Thursday, June 12th. HC Wainwright upped their price target on shares of Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, May 28th. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. BTIG Research reaffirmed a "buy" rating on shares of Liquidia Technologies in a research note on Tuesday, May 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating on shares of Liquidia Technologies in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Liquidia Technologies presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.89.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).